Hydrafacial v. Sinclair Pharma & Viora: Five-Patent Hydrodermabrasion Dispute Stayed for Mediation
Hydrafacial, LLC brought a five-patent infringement action against Sinclair Pharma Limited, Sinclair Pharma US, Inc., and Viora, Inc. in the Central District of California, asserting a portfolio of hydrodermabrasion device patents. After 278 days, the court stayed and administratively closed proceedings for 60 days to allow mediation — a resolution path that suggests the parties see a negotiated outcome as viable.
Five-Patent Hydrodermabrasion Portfolio Dispute Diverted to Mediation
Hydrafacial, LLC filed this infringement action on July 24, 2024, in the Central District of California against Sinclair Pharma Limited and its US subsidiary Sinclair Pharma US, Inc., together with Viora, Inc. The complaint asserted five United States patents — US11865287B2, US10357642B2, US9550052B2, US11446477B2, and US10357641B2 — all directed to hydrodermabrasion products and devices. The breadth of the patent portfolio suggests Hydrafacial sought comprehensive coverage across both core device architecture and method-of-use claims.
The case was stayed and administratively closed on April 28, 2025, following a joint stipulation by all parties to pursue mediation. The court granted the stay for 60 days until June 20, 2025, requiring a status report on the outcome of mediation by that date. Critically, the order stipulates that failure to file a timely status report will result in the action being deemed dismissed as of June 21, 2025 — a conditional dismissal mechanism that creates a structural incentive for the parties to resolve or report promptly.
The 278-day timeline from filing to stay is consistent with early-stage pre-discovery resolution efforts in the Central District of California, where mediation referrals before substantive motion practice are increasingly common in device patent disputes. The joint nature of the stipulation — filed by both plaintiff and all defendants — suggests that both sides assessed continued litigation as less attractive than a negotiated outcome, though the public record does not disclose the terms under discussion or whether any licensing framework is on the table.
Filing to Case Stayed in 278 days
278 days from filing to stay — typical pre-trial phase for multi-patent device disputes in C.D. Cal.
Case stayed pending mediation: what the conditional closure means for both parties
Joint stipulation stay — not a dismissal on the merits
A joint stipulation to stay and administratively close a case pending mediation is a procedural tool, not a ruling on the merits of infringement or validity. The court retains jurisdiction throughout the 60-day window. The conditional deemed-dismissal trigger — activated only if no status report is filed — means the parties control the next step. No claim construction, no summary judgment, no damages assessment has occurred.
Procedural stay — no merits rulingHydrafacial preserves all claims and leverage for mediation
By securing a stay rather than a dismissal, Hydrafacial maintains its full five-patent infringement claims intact. The conditional dismissal mechanism gives Hydrafacial a credible threat: if mediation fails and no status report is filed, the action can be revived or allowed to lapse on Hydrafacial’s terms. The asserted portfolio — spanning five patents across hydrodermabrasion device and method claims — remains enforceable throughout this period.
Claims intact — leverage preservedSinclair Pharma and Viora avoid answer deadline during mediation window
A key concession for defendants is that their deadline to answer or otherwise respond to the complaint is deferred until after the stay, should the case remain unresolved. This insulates Sinclair Pharma and Viora from having to commit to invalidity or non-infringement positions during mediation — a significant tactical benefit when negotiating licensing terms. The three-defendant structure (two Sinclair entities plus Viora) suggests potential for differentiated settlement outcomes.
Answer deferred — negotiation flexibilityMediation path signals sector consolidation pressure in aesthetic devices
The decision by all parties to pursue mediation in a five-patent dispute involving a dominant brand (Hydrafacial) and two commercial competitors suggests that the aesthetic device sector is experiencing IP-driven competitive pressure that parties prefer to resolve commercially. A licensing outcome, if reached, could set royalty benchmarks for hydrodermabrasion technology that affect other market participants beyond the immediate defendants.
Licensing benchmarks at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Hydrafacial, LLC | Company | Aesthetic device company — holder of US11865287B2 and 4 further hydrodermabrasion patentsSearch in Eureka ↗ |
| Defendant | Sinclair Pharma Limited | Individual | Sinclair Pharma Limited and US subsidiary, plus Viora, Inc. — aesthetic device competitorsSearch in Eureka ↗ |
| Co-Defendant | Sinclair Pharma US, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Viora, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Ali Razai | Attorney | Counsel for Hydrafacial, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Benjamin J. Everton | Attorney | Counsel for Hydrafacial, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Christian D. Boettcher | Attorney | Counsel for Hydrafacial, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Juliana H. Kirby | Attorney | Counsel for Hydrafacial, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Morgan, Lewis & Bockius, LLP | Law Firm | Representing Hydrafacial, LLCSearch in Eureka ↗ |
| Defendant counsel | Ashley M. Koley | Attorney | Counsel for Sinclair Pharma LimitedSearch in Eureka ↗ |
| Defendant counsel | Jack T. Carroll | Attorney | Counsel for Sinclair Pharma LimitedSearch in Eureka ↗ |
| Defendant counsel | Kevin J. Malaney | Attorney | Counsel for Sinclair Pharma LimitedSearch in Eureka ↗ |
| Defendant counsel | R. Spencer Montei | Attorney | Counsel for Sinclair Pharma LimitedSearch in Eureka ↗ |
| Defendant law firm | Foley & Lardner, LLP | Law Firm | Representing Sinclair Pharma LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Central District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order reflects a purely procedural disposition: no claim has been adjudicated on its merits, no infringement finding has been made, and no validity ruling has issued. The deemed-dismissal mechanic embedded in the stay order is notable — it functions as a soft deadline that gives the parties conditional finality without requiring active judicial intervention. The deferral of defendants’ answer deadline is an unusual concession that preserves maximum negotiating flexibility for all sides while maintaining the court’s oversight role through the required status report.
US11865287B2 — Hydrodermabrasion Device and System Patents
The five asserted patents — US11865287B2, US10357642B2, US9550052B2, US11446477B2, and US10357641B2 — collectively cover hydrodermabrasion device systems, handpiece configurations, fluid delivery mechanisms, and associated treatment methods. The application dates span from US14/698673 (an earlier priority application) through to US18/094884, suggesting a deliberate continuation strategy designed to extend coverage as the commercial product evolved. This layered patent family structure is characteristic of a dominant market participant seeking to maintain broad exclusivity across successive product generations.
For competitors and adjacent device manufacturers, the breadth of this portfolio — five patents spanning both apparatus and method claims — creates substantial freedom-to-operate risk. Even incremental design changes to handpiece geometry, fluid delivery parameters, or system controls may fall within one or more continuation claims. The aesthetic device sector, which includes both professional-use and consumer-grade hydrodermabrasion systems, should treat this portfolio as a high-priority FTO target, particularly given Hydrafacial’s demonstrated willingness to assert all five patents simultaneously against multiple defendants.
Should you run an FTO against US11865287B2 and the Hydrafacial patent family?
Any company developing, distributing, or OEM-sourcing hydrodermabrasion devices, skin resurfacing systems, or adjacent fluid-assisted exfoliation products should treat this five-patent family as a priority FTO target. The asserted patents cover a range of apparatus and method claims, meaning both device manufacturers and their distribution partners — as illustrated by the Sinclair/Viora defendant structure — may face exposure. R&D teams should map their device architecture, handpiece design, and fluid system specifications against the independent claims of all five patents before commercial launch.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim scope of US11865287B2, US10357642B2, US9550052B2, US11446477B2, and US10357641B2 simultaneously, flagging overlap risk at the claim element level. Eureka’s continuation chain analysis will also identify any pending continuations from this family that have not yet issued — a critical blind spot in manual FTO workflows. For in-house IP teams tracking this litigation, Eureka’s case monitoring tools provide real-time alerts on the June 2025 status report filing and any subsequent enforcement activity.
Run a freedom-to-operate analysis on US11865287B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hydrodermabrasion and Aesthetic Device Patent Cases in C.D. Cal.
Explore comparable patent infringement actions asserting aesthetic device and hydrodermabrasion technology patents in the Central District of California.
What this case signals for the aesthetic device IP landscape
A five-patent stay-for-mediation in aesthetic devices is rare — it signals both portfolio strength and sector-wide licensing pressure.
Five-patent assertions signal portfolio enforcement strategy, not opportunistic filing
Asserting five patents across hydrodermabrasion device and method claims in a single action is consistent with a portfolio enforcement strategy designed to foreclose design-around options. Companies operating in the hydrodermabrasion or adjacent aesthetic device space should audit their product lines against all five asserted patents, not just the lead patent.
Joint mediation stipulations in C.D. Cal. often precede licensing agreements, not outright dismissals
In Central District of California device patent cases, joint stipulations to stay pending mediation most commonly resolve in licensing or co-existence agreements rather than voluntary dismissal with no terms. The structured 60-day window with a conditional deemed-dismissal suggests both sides have framework-level terms to discuss — monitoring the June 2025 status report will be critical.
Hydrafacial v Sinclair — key questions answered
Hydrafacial asserted five US patents: US11865287B2, US10357642B2, US9550052B2, US11446477B2, and US10357641B2. All relate to hydrodermabrasion products, covering device architecture, handpiece configurations, fluid delivery systems, and treatment methods. The patents span multiple continuation applications, suggesting a deliberate portfolio strategy to maintain broad coverage.
All parties filed a joint stipulation requesting a 60-day stay to pursue mediation. The Central District of California court granted the stay on April 28, 2025, administratively closing the case until June 20, 2025. The order includes a conditional deemed-dismissal: if the parties fail to file a status report by June 20, 2025, the action is deemed dismissed as of June 21, 2025.
No. The stay is a purely procedural disposition. No merits ruling on infringement, validity, or damages was made. The court retains jurisdiction during the 60-day window, and all five patent claims remain unresolved. The administrative closure does not constitute a judgment for either party.
The order provides that if the parties fail to file a status report by June 20, 2025, the action shall be deemed dismissed as of June 21, 2025. This creates a hard deadline that incentivises either resolution or active case management. It is a C.D. Cal. administrative tool to manage the docket while preserving the parties’ ability to resolve privately — but it does not specify whether any deemed dismissal would be with or without prejudice.
The case centres on hydrodermabrasion products. Hydrafacial, a leading brand in professional-grade hydrodermabrasion devices, alleged that products offered by Sinclair Pharma (through its UK parent and US subsidiary) and Viora, Inc. infringe its five-patent portfolio. The specific accused products are not detailed in the publicly available court record reviewed here.
PatSnap Eureka searches patents and litigation data to answer instantly.